La FDA aprueba un nuevo tratamiento para la enfermedad de Alzheimer

BioGen’s “Aduhelm” is a monthly injection intended to slow cognitive decline in patients with early stages of the disease. The FDA granted the drug approval as a new clinical trial begins.

Fuente: Youtube